Anti Deep Ze 7.22.0203453
figure 2: use of morphology-based cnn to identify senescent cells. (a) representative images of the class distribution of the training set and test set. (b) roc curve. (c) the mean accuracy and standard error of the seven experiments are shown. (d) confusion matrices are shown for the deep-sesmo test set. senescent cells show morphological features characteristic of senescent cells.
metformin is a biguanide anti-diabetic drug and a potential anti-aging drug. here, we screened the potential of metformin as an anti-aging drug by deep-sesmo, using deep-sesmo, the drug library (screen-well compound library, enzo), and the stress induction methods (h2o2, cpt, and replication). the senescence score was calculated using three networks trained by h2o2, cpt, and h2o2 and cpt. the senescence score was converted to a ranking of senescence score in each analysis. drug-screening was evaluated by two compounds (10nm terreic acid, and 5m daidzein) and four compounds (10nm y-276322, 500nm y-27632, 5m daidzein, and 100nm pd-98059) by deep-sesmo. y-276322, and pd-98059 are inhibitors of the rho-associated protein kinase (rock), while y-27632 is a known inhibitor of the rock. a visualisation of the senescence score ranking was performed by the plotly package. to detect a cell-type-specific drug, the senescence score of each cell type was compared to the control sample. the senescence scores of huvecs and hmscs were compared to both the control and each drug sample. to calculate the anti-senescent ranking of drugs, the median of the senescence score ranking was sorted.
p. falciparum is the most virulent of the five human malaria parasites and causes the most severe forms of human malaria, severe malaria anemia and cerebral malaria. malaria is still a major health problem in tropical and subtropical regions, particularly in africa. drug resistance is a major problem and there is an urgent need for new antimalarial drugs. a new class of antiparasitic compound, miltefosine, has been shown to be active against p. falciparum in vitro, but no animal model of malaria has been established. therefore, we aimed to establish a new animal model of malaria, and to test the antimalarial activity of miltefosine. we developed an animal model of p. falciparum infection in c57bl/6 mice by intraperitoneal injection of p. berghei nk65 strain anka clone2. we infected mice with 2.0-5.0% of parasitemia and confirmed the successful establishment of the infection. we then investigated the antimalarial activity of miltefosine. miltefosine was administered orally at 5mg/kg, once daily, for 4 days. the survival rate of mice infected with p. berghei anka clone 2 was not significantly different between the control and miltefosine-treated group. on day 7 after treatment, parasitemia in the control group peaked and decreased to 10%-20% by day 12, whereas a continuous increase in parasitemia was observed in the miltefosine-treated group. the percentage of parasitized red blood cells in the control group was 79.4% on day 7 and 98.6% on day 12. in contrast, the percentage of parasitized red blood cells in the miltefosine-treated group was 34.6% on day 7 and 96.5% on day 12. these results suggest that oral administration of miltefosine caused the reduction of the number of parasitized red blood cells and is a useful tool for the investigation of antimalarial drugs.